{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:42Z","timestamp":1781636082030,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mpox disease is endemic to several regions of sub-Saharan Africa, with transmission occurring through close contact with infected animals or humans. Increasing case numbers in East Africa led the African Centre for Disease Control and Prevention to declare a Public Health Emergency of Continental Security on 13th August 2024 related to a new virus variant (clade 1b). The Mpox CARE study aims to establish clinical and epidemiology data to develop innovative immunodiagnostic tests, facilitating models for sub-clinical disease exposure, transmission and future vaccine strategies (Part A). Furthermore, we aim to evaluate and optimize vaccine cold-chain (VCC) systems to support Mpox vaccine deployment while ensuring the continued provision of childhood immunizations (Part B).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study will recruit up to 650 participants to three study groups according to Mpox exposure status and\/or vaccination in Rwanda. All enrolled participants will be asked to provide demographic information, relevant medical history, up to 20mLs of venous blood and a dried blood spot capillary blood sample. For Part A of the study, samples will undergo testing for quantitative analysis of total serum antibody to Mpox specific proteins using an enzyme-linked immunosorbent assay (ELISA) and test a novel point-of-care (POC) lateral flow test to determine positive\/negative qualitative serostatus. For Part B, we will collect data on VCC equipment, inventories and methods of vaccine distribution. The results of this project aim to (a) validate a blood-based ELISA assay for the detection of Mpox immunity in a target population of Rwanda, (b) generate an estimate of sero-positivity to Mpox in Rwanda, (c) evaluate the clinical performance of a novel POC lateral flow test for Mpox serostatus and (d) understand the VCC requirements for additional vaccine deployment for disease control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Detecting antibodies for sub-clinical Mpox cases improves disease mapping and transmission patterns in endemic African regions. Novel POC immunodiagnostics can enhance community healthcare and decentralise efforts to understand Mpox seroepidemiology. Understanding VCC requirements for deployment of genetic vaccines, alongside regular vaccine provision to pregnant women, and children offers insights for management of future vaccine-preventable disease outbreaks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trail registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov trial registration number NCT06887556, registered 20th March 2025.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-12809-6","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:53:10Z","timestamp":1771001590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mpox comprehensive assessment for responsive immunisation in emergency outbreaks (MpoxCARE): study protocol"],"prefix":"10.1186","volume":"26","author":[{"given":"Karishma","family":"Gokani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Semukunzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Rukundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian E.","family":"Faustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Musabyimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley David","family":"Otter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Muvunyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Aird","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The MpoxCARE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopold","family":"Bitunguhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prosper","family":"Ingabire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Iradukunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Izuwayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Kabalisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hin Fai","family":"Kowk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Mutesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonce","family":"Rukundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Simugomwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie Vianney","family":"Uwimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philemon","family":"Uwishema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"12809_CR1","doi-asserted-by":"publisher","first-page":"198932","DOI":"10.1016\/j.virusres.2022.198932","volume":"322","author":"E Lansiaux","year":"2022","unstructured":"Lansiaux E, Jain N, Laivacuma S, Reinis A. The virology of human Monkeypox virus (hMPXV): A brief overview. Virus Res. 2022;322:198932.","journal-title":"Virus Res"},{"issue":"1","key":"12809_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00705-022-05677-3","volume":"168","author":"S Sabeena","year":"2023","unstructured":"Sabeena S. The changing epidemiology of Monkeypox and preventive measures: an update. Arch Virol. 2023;168(1):31.","journal-title":"Arch Virol"},{"issue":"4","key":"12809_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.virs.2022.07.006","volume":"37","author":"Q Gong","year":"2022","unstructured":"Gong Q, Wang C, Chuai X, Chiu S. Monkeypox virus: a re-emergent threat to humans. Virol Sin. 2022;37(4):477\u201382.","journal-title":"Virol Sin"},{"issue":"2","key":"12809_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/cid\/cit703","volume":"58","author":"AM McCollum","year":"2014","unstructured":"McCollum AM, Damon IK. Human Monkeypox. Clin Infect Dis. 2014;58(2):260\u20137.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"12809_CR5","doi-asserted-by":"publisher","first-page":"e0009222","DOI":"10.1128\/cmr.00092-22","volume":"35","author":"S Elsayed","year":"2022","unstructured":"Elsayed S, Bondy L, Hanage WP. Monkeypox virus infections in humans. Clin Microbiol Rev. 2022;35(4):e0009222.","journal-title":"Clin Microbiol Rev"},{"issue":"Pt 10","key":"12809_CR6","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1099\/vir.0.81215-0","volume":"86","author":"AM Likos","year":"2005","unstructured":"Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, et al. A Tale of two clades: Monkeypox viruses. J Gen Virol. 2005;86(Pt 10):2661\u201372.","journal-title":"J Gen Virol"},{"issue":"8","key":"12809_CR7","doi-asserted-by":"publisher","first-page":"e2220415120","DOI":"10.1073\/pnas.2220415120","volume":"120","author":"JL Americo","year":"2023","unstructured":"Americo JL, Earl PL, Moss B. Virulence differences of Mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model. Proc Natl Acad Sci U S A. 2023;120(8):e2220415120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"12809_CR8","doi-asserted-by":"publisher","first-page":"e0010141","DOI":"10.1371\/journal.pntd.0010141","volume":"16","author":"EM Bunge","year":"2022","unstructured":"Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141.","journal-title":"PLoS Negl Trop Dis"},{"key":"12809_CR9","doi-asserted-by":"publisher","first-page":"102402","DOI":"10.1016\/j.tmaid.2022.102402","volume":"49","author":"N Luna","year":"2022","unstructured":"Luna N, Ramirez AL, Munoz M, Ballesteros N, Patino LH, Castaneda SA, et al. Phylogenomic analysis of the Monkeypox virus (MPXV) 2022 outbreak: emergence of a novel viral lineage? Travel Med Infect Dis. 2022;49:102402.","journal-title":"Travel Med Infect Dis"},{"issue":"7","key":"12809_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/jama.2022.12513","volume":"328","author":"JB Nuzzo","year":"2022","unstructured":"Nuzzo JB, Borio LL, Gostin LO. The WHO declaration of Monkeypox as a global public health emergency. JAMA. 2022;328(7):615\u20137.","journal-title":"JAMA"},{"key":"12809_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/bmj.p1190","volume":"381","author":"C Carlson","year":"2023","unstructured":"Carlson C, Katz R. WHO ends public health emergency designation for Mpox. BMJ. 2023;381:1190.","journal-title":"BMJ"},{"issue":"7","key":"12809_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMoa2411368","volume":"392","author":"N Ndembi","year":"2025","unstructured":"Ndembi N, Folayan MO, Komakech A, Mercy K, Tessema S, Mbala-Kingebeni P, et al. Evolving epidemiology of Mpox in Africa in 2024. N Engl J Med. 2025;392(7):666\u201376.","journal-title":"N Engl J Med"},{"key":"12809_CR13","unstructured":"Speech of the Director General \/ Africa CDC on the Declaration of Mpox as a Public Health Emergency of Continental Security (PHECS) [press release]. 13th. August 2024. 2024."},{"issue":"10472","key":"12809_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(24)02353-5","volume":"405","author":"CG Beiras","year":"2025","unstructured":"Beiras CG, Malembi E, Escrig-Sarreta R, Ahuka S, Mbala P, Mavoko HM, et al. Concurrent outbreaks of Mpox in Africa-an update. Lancet. 2025;405(10472):86\u201396.","journal-title":"Lancet"},{"issue":"10","key":"12809_CR15","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/s41591-024-03130-3","volume":"30","author":"EH Vakaniaki","year":"2024","unstructured":"Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O\u2019Toole A, Wawina-Bokalanga T, Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I lineage in Eastern Democratic Republic of the congo. Nat Med. 2024;30(10):2791\u20135.","journal-title":"Nat Med"},{"key":"12809_CR16","unstructured":"World Health Organization. Mpox: multi-country external situation report no. 47 [Internet]. Geneva: World Health Organization; 2025 Feb 13."},{"key":"12809_CR17","unstructured":"First meeting of the International Health Regulations. Emergency Committee regarding the upsurge of mpox 2024 [press release]. 19 August 2024 2024. 2005."},{"issue":"12","key":"12809_CR18","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S1473-3099(22)00574-6","volume":"22","author":"GA Poland","year":"2022","unstructured":"Poland GA, Kennedy RB, Tosh PK. Prevention of Monkeypox with vaccines: a rapid review. Lancet Infect Dis. 2022;22(12):e349\u201358.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"12809_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nm1261","volume":"11","author":"Y Edghill-Smith","year":"2005","unstructured":"Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against Monkeypox virus. Nat Med. 2005;11(7):740\u20137.","journal-title":"Nat Med"},{"key":"12809_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.0105-2896.2006.00392.x","volume":"211","author":"IJ Amanna","year":"2006","unstructured":"Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev. 2006;211:320\u201337.","journal-title":"Immunol Rev"},{"issue":"1","key":"12809_CR21","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1038\/s41467-023-41587-x","volume":"14","author":"AD Otter","year":"2023","unstructured":"Otter AD, Jones S, Hicks B, Bailey D, Callaby H, Houlihan C, et al. Monkeypox virus-infected individuals Mount comparable humoral immune responses as Smallpox-vaccinated individuals. Nat Commun. 2023;14(1):5948.","journal-title":"Nat Commun"},{"issue":"11","key":"12809_CR22","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","volume":"23","author":"H Cohn","year":"2023","unstructured":"Cohn H, Bloom N, Cai GY, Clark JJ, Tarke A, Bermudez-Gonzalez MC, et al. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study. Lancet Infect Dis. 2023;23(11):1302\u201312.","journal-title":"Lancet Infect Dis"},{"issue":"10459","key":"12809_CR23","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0140-6736(24)02132-9","volume":"404","author":"P Adepoju","year":"2024","unstructured":"Adepoju P. Vaccination under way as Mpox cases continue to rise. Lancet. 2024;404(10459):1184.","journal-title":"Lancet"},{"key":"12809_CR24","unstructured":"World Health Organization. Global mpox trends [Internet]. Geneva: World Health Organization; 2025."},{"key":"12809_CR25","doi-asserted-by":"crossref","unstructured":"Jones S, Hicks B, Callaby H, Bailey D, Gordon NC, Rampling T et al. Assessment of MpoxPlex, a high-throughput and multiplexed immunoassay: a diagnostic accuracy study. Lancet Microbe. 2025:100987.","DOI":"10.1016\/j.lanmic.2024.100987"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12809-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12809-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:14:46Z","timestamp":1781633686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12809-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12809"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12809-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol has been reviewed and approved by Rwanda National Ethics Committee (reference RNEC589\/2024) and the University of Birmingham (reference ERN_3084). The study will be conducted in accordance with the principles of the Declaration of Helsinki and relevant regulations of the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice. All amendments to the protocol will be discussed with RNEC. The sponsor is University of Birmingham, who can be contacted on adm-researchgov@adf.bham.ac.uk and provide indemnity or compensation for harm arising as a consequence of the research subjects\u2019 participation in the trial. All participants will provide documented informed consent to participate. Participation in the trial is strictly voluntary, and withdrawal can occur at any point in the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There was no public involvement in development of the research question or study design. However, the planned semi-structured interviews or focus groups with study participants and healthcare workers will address PPI aspects to the project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CAG has worked as a Principal Investigator with many commercial vaccine manufacturers including, and not restricted to, AstraZeneca, Pfizer\/BNT, Moderna, Johnson&Johnson, CureVac, Novovax, Valneva, Gritstone. None of these present a conflict of interest in this study but are declared in the spirit of full transparency. All other others have no competing interests to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"590"}}